Vanda Pharma announces Non-24 Hour Sleep Disorder - 15-Jun-2012

Vanda Pharma announced at the SLEEP conference of the Associated Professional Sleep Societies that 70% of totally blind people with sleep complaints suffer from Non-24 Hour Disorder, a circadian rhythm disorder characterised by a chronically misaligned body clock. In a poster presented at the conference " Seventy per cent of totally blind people with sleep complaints are not entrained to the 24 hour clock" data were reported on the endogenous circadian period for the first 143 subjects enrolled in the SET study (study 3201)a Phase III trial in totally blind patients. Seventy per cent were diagnosed with the Non-24 Hour circadian period showing the subjects internal clock delay of a median of 24.45 hours meaning the subjects internal clocks delay of a median of 27 minutes per day.The effect is cumulative. Vanda is currently studying the effect of tasimelteon, an agonist of melatonin M1 and M2 receptors in Non-24 in two Phase III trials called SET and RESET which are expected to be completed during 2012.